TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07391722: A Multicentre, Randomized, Double-Blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of DNV001 Injection at Different Dosages in Patients With Primary Hypercholesterolaemia or Mixed Hyp

Sponsor: Hangzhou Dinovate Biotech Co., Ltd · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 120 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07391722 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07391722 Rescue Dossier →